CUREVERSE Inc. - FuturePlay Portfolio Company Details

The company is a small-molecule drug discovery and development company. Guided by its proprietary research philosophy, "Right Structure," the company designs molecular structures with high target selectivity and develops treatments for intractable diseases, including neurodegenerative disorders such as Alzheimer's disease, autoimmune diseases, and solid tumors. Its lead pipeline candidate, CV-01, is an oral Alzheimer's disease treatment designed to alleviate neuroinflammation by activating the KEAP1/NRF2 pathway. CV-01 demonstrated favorable safety and tolerability in a Phase 1 clinical trial in Korea, and the company is currently preparing to advance into Phase 2 clinical trials. The company is also developing follow-on pipeline candidates, including CV-02 for autoimmune diseases and CV-03 for solid tumors. In 2024, the company entered into a licensing agreement with Italy-based Angelini Pharma for CV-01, granting global development and commercialization rights excluding Korea and China, in a deal valued at up to USD 370 million. By successfully securing a global licensing agreement at the preclinical stage, the company demonstrated its research and development capabilities. Building on this achievement, the company is pursuing global clinical development and a potential initial public offering (IPO).